Peters GR - Search Results

1

Effect of age and gender on tirilazad pharmacokinetics in humans.

Hulst LK, Fleishaker JC, Peters GR, Harry JD, Wright DM, Ward P. Hulst LK, et al. Among authors: peters gr. Clin Pharmacol Ther. 1994 Apr;55(4):378-84. doi: 10.1038/clpt.1994.45. Clin Pharmacol Ther. 1994. PMID: 8162663

2

Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF.

Girgis IG, Patel MR, Peters GR, Moore KT, Mahaffey KW, Nessel CC, Halperin JL, Califf RM, Fox KA, Becker RC. Girgis IG, et al. Among authors: peters gr. J Clin Pharmacol. 2014 Aug;54(8):917-27. doi: 10.1002/jcph.288. Epub 2014 Mar 26. J Clin Pharmacol. 2014. PMID: 24668660 Free article. Clinical Trial.

3

Pharmacokinetics of tirilazad in healthy male subjects at doses above 6 mg/kg/day.

Fleishaker JC, Peters GR. Fleishaker JC, et al. Among authors: peters gr. Int J Clin Pharmacol Ther. 1997 Jan;35(1):28-32. Int J Clin Pharmacol Ther. 1997. PMID: 9021439 Clinical Trial.

4

Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination.

Ko H, Cathcart KS, Griffith DL, Peters GR, Adams WJ. Ko H, et al. Among authors: peters gr. Antimicrob Agents Chemother. 1989 Mar;33(3):356-61. doi: 10.1128/AAC.33.3.356. Antimicrob Agents Chemother. 1989. PMID: 2729930 Free PMC article. Clinical Trial.

5

Phenytoin causes a rapid increase in 6 beta-hydroxycortisol urinary excretion in humans--a putative measure of CYP3A induction.

Fleishaker JC, Pearson LK, Peters GR. Fleishaker JC, et al. Among authors: peters gr. J Pharm Sci. 1995 Mar;84(3):292-4. doi: 10.1002/jps.2600840305. J Pharm Sci. 1995. PMID: 7616365

6

Lack of pharmacokinetic interaction between cimetidine and tirilazad mesylate.

Fleishaker JC, Hulst LK, Peters GR. Fleishaker JC, et al. Among authors: peters gr. Pharm Res. 1994 Feb;11(2):341-4. doi: 10.1023/a:1018988331700. Pharm Res. 1994. PMID: 8165199 Clinical Trial. No abstract available.

7

Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger: I. Single-dose administration.

Fleishaker JC, Peters GR, Cathcart KS. Fleishaker JC, et al. Among authors: peters gr. J Clin Pharmacol. 1993 Feb;33(2):175-81. doi: 10.1002/j.1552-4604.1993.tb03940.x. J Clin Pharmacol. 1993. PMID: 8382708 Clinical Trial.

8

Hormonal effects on tirilazad clearance in women: assessment of the role of CYP3A.

Fleishaker JC, Pearson LK, Pearson PG, Wienkers LC, Hopkins NK, Peters GR. Fleishaker JC, et al. Among authors: peters gr. J Clin Pharmacol. 1999 Mar;39(3):260-7. J Clin Pharmacol. 1999. PMID: 10073325 Clinical Trial.

9

Biotransformation of tirilazad in human: 4. effect of finasteride on tirilazad clearance and reduced metabolite formation.

Fleishaker JC, Pearson PG, Wienkers LC, Pearson LK, Moore TA, Peters GR. Fleishaker JC, et al. Among authors: peters gr. J Pharmacol Exp Ther. 1998 Nov;287(2):591-7. J Pharmacol Exp Ther. 1998. PMID: 9808685 Clinical Trial.

10

Induction of tirilazad clearance by phenytoin.

Fleishaker JC, Pearson LK, Peters GR. Fleishaker JC, et al. Among authors: peters gr. Biopharm Drug Dispos. 1998 Mar;19(2):91-6. doi: 10.1002/(sici)1099-081x(199803)19:2<91::aid-bdd78>3.0.co;2-t. Biopharm Drug Dispos. 1998. PMID: 9533108 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results